6.38
Precedente Chiudi:
$6.48
Aprire:
$6.4
Volume 24 ore:
1.21M
Relative Volume:
0.89
Capitalizzazione di mercato:
$646.68M
Reddito:
-
Utile/perdita netta:
$-167.48M
Rapporto P/E:
-3.2718
EPS:
-1.95
Flusso di cassa netto:
$-197.47M
1 W Prestazione:
+1.75%
1M Prestazione:
-16.93%
6M Prestazione:
-54.20%
1 anno Prestazione:
-53.09%
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Confronta DAWN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DAWN
Day One Biopharmaceuticals Inc
|
6.38 | 635.54M | 0 | -167.48M | -197.47M | -1.95 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-09 | Reiterato | Needham | Buy |
2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
2024-04-24 | Reiterato | Needham | Buy |
2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
2023-02-08 | Iniziato | CapitalOne | Overweight |
2023-02-03 | Iniziato | Oppenheimer | Perform |
2022-12-15 | Iniziato | H.C. Wainwright | Buy |
2022-12-14 | Iniziato | Needham | Buy |
2022-12-05 | Iniziato | Goldman | Buy |
2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
Trend Tracker for (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down – Here’s What Happened - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Needham Adjusts Price Target for DAWN to $27, Maintains Buy Rati - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Reports First Quarter 2025 Financial Results and Corporate Progress - GlobeNewswire
Earnings call transcript: Day One Biopharmaceuticals beats Q1 2025 EPS forecast - Investing.com
Day One Biopharmaceuticals Q1 2025 slides: OJEMDA revenue grows 11% amid market challenges - Investing.com Canada
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Day One Biopharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Pr - GuruFocus
Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Holdings of Day One Biopharmaceuticals Inc (DAWN) are aligned with the stars - Sete News
Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Is Day One Biopharmaceuticals Inc (DAWN) worth investing in despite its overvalued state? - uspostnews.com
Examining the Potential Price Growth of Day One Biopharmaceuticals Inc (DAWN) - knoxdaily.com
Market Momentum Report: Xeris Biopharma Holdings Inc (XERS)’s Positive Close at 4.41 - DWinneX
Azitra Inc (AZTR)’s Day in Review: Closing at 0.30, Down by -6.51 - DWinneX
SuperCom Ltd (SPCB)’s Day in Review: Closing at 6.19, Down by -22.04 - DWinneX
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):